Exelon Patch is a once-daily skin patch containing rivastigmine, and it may suit people with certain stages of Alzheimer's or Parkinson's dementia. It may support thinking or memory, but benefits vary, and digestive problems, weight loss, skin allergy, and medication errors are important risks. The treatment does not cure dementia. Its value depends on the diagnosis, tolerability, other health conditions, and whether a caregiver can manage the patch safely.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who may qualify?
- How much benefit can families expect?
- How is the dose increased?
- What are the main risks?
- Preventing patch errors
Who may qualify?
The FDA-approved label covers mild, moderate, and severe dementia of the Alzheimer's type. It also covers mild-to-moderate dementia associated with Parkinson's disease, according to the National Library of Medicine's DailyMed label. The approved evidence does not establish the patch for every dementia diagnosis.
Vascular, frontotemporal, and unspecified dementia are not among its U.S. indications. A person may be a candidate when: A prior patch-site reaction suggesting allergic contact dermatitis rules out treatment. This is different from assuming that every small area of temporary irritation represents an allergy; a clinician should assess the reaction.
- The diagnosis and dementia stage match an approved use.
- A clinician determines that the potential benefit justifies the risks.
- The person has no known allergy to rivastigmine or related carbamates.
- A caregiver or patient can reliably remove and replace the patch each day.
How much benefit can families expect?
MedlinePlus says rivastigmine may improve thinking and memory or slow their loss, but it does not cure Alzheimer's or Parkinson's dementia. Response differs from person to person, as explained in the National Library of Medicine's rivastigmine guidance. In a 24-week placebo-controlled Alzheimer's trial, the 9.5-mg/24-hour patch had a statistically significant 1.8-point advantage over placebo on the ADAS-Cog cognitive scale.
That scale measures cognitive performance in a study; the result does not mean every patient will notice the same improvement in daily life. A realistic goal is symptom support, not reversal of the disease. Families should discuss what changes would count as worthwhile, such as steadier cognitive performance, while also watching whether side effects outweigh any benefit.
How is the dose increased?
Treatment generally begins with one 4.6-mg/24-hour patch each day. If the person tolerates it, the dose may increase no sooner than every four weeks. The 9.5-mg/24-hour patch is the minimum effective dose listed in the FDA-approved label.
The maximum is 13.3 mg/24 hours. Gradual increases matter because several adverse effects are dose-related. Caregivers should follow the prescribed strength rather than increasing it because improvement seems limited. A modest or unclear response does not make faster dose escalation safe.
What are the main risks?
Nausea, vomiting, diarrhea, reduced appetite, and weight loss are key dose-related risks. In one trial, at least 7% loss of baseline body weight occurred in 8% of people using the 9.5-mg patch, compared with 6% receiving placebo.
Clinicians should use added caution when a person has: These factors do not automatically exclude treatment. They can affect dosing, monitoring, or whether another option has a better risk-benefit balance.
- Low body weight
- Mild-to-moderate liver impairment
- Cardiac conduction disease
- Asthma or COPD
- Increased ulcer risk
Preventing patch errors
Remove the old patch before applying the new one, and confirm that only one patch is being worn. Multiple-patch errors have caused serious reactions, hospitalization, and, rarely, death, according to the FDA-approved DailyMed safety information. A simple daily routine can reduce this risk:.
- Find and remove yesterday's patch.
- Check the skin to confirm no other patch remains.
- Apply only the prescribed new patch.
- Record the change so another caregiver does not repeat it.
